ISSUES

Contents

(Innovations in Companion Animal Medicine Session 3)

AI-driven Personalized Medicine for Pet Cancer Care

Sungwon Lim_Chief Executive Officer, ImpriMed

Dr. Sungwon Lim gave a talk about his company ImpriMed which provides an AI-driven personalized medicine for pet Cancer Care. ImpriMed helps veterinary oncologists find the most effective anti-cancer drugs for individual cancer.

Dr. Lim talked a little bit about how big the market is and the cancer space for pet cancer in the US and explained that there are very limited number of veterinary inclusions in the U.S. meaning that they are super busy to deal with and to handle old big number of the large number of patients. This scenario actually helps ImpriMed as a company for an easier market acquisition of their service and penetrate the market to let the doctors use ImpriMed’s service for more patients and for the insurance companies and reimbursement. ImpriMed is a company that has already a USDA and an FDA.

Image Sources: Zoom Presentation Screenshot by Dr. Sungwon Lim

ImpriMed’s mission is that personalizing drug treatment for cat cancer patients with an accurate prediction using the AI with unique approach letting patients own life cancer cells meet artificial intelligence by using the live cancer cell based analytics getting the patient sample from the hospitals, generating a lot of data at own lab that received patient clinical samples and then based on the tumor biopsy, separating out the patient’s cancer cells and then generate a drug sensitivity data immune subtype data and the genetic information data and then AI model combine these data raw data together with a patient information and then that goes into final report that predicts which drug works best or each drug should not be used for these patients. These reports help doctors to understand the cancer better and find out the effective treatment of problems and responses in the patient body. When the patients are treated with the drugs, this report is delivered as first brief reports data in three to four days. Once received, the sample collection to the final report, turnaround time is six days with the service position between diagnosis and treatment. ImpriMed is focusing on the development of some tools to provide oncologists risk screening and treatment response prediction and then problems evaluation. The company’s goal is to help oncologists find out the personalized cancer treatment regimen with the best prediction about increment technologies in the live cancer cell-based company to measure the drug to cell interaction being tackled and developed an optimal media or the incremented optimum media to keep the cells alive up to 70 to 80 percent up to maximum two weeks and maximize the cell variability right after the sample collection on-site at the clinic. Dr. Lim also mentioned the data that generates the drug sensitivity flow cytometry and then par data that goes into the AI model especially machine learning model as input variables.

ImpriMed’s first commercialized service is blood cancer which was provided for two hospitals that was well received in the US. They provide services to 32 different States including Hawaii and Alaska. Two or more than one 130 plus hospitals they have provided more than 8,000 reports to the patients and then doctors are very satisfied with the quality and the contents of ImpriMed’s service. Dr. Lim also proudly introduced his team with very strong leaders in the field of bioscience, data science, commercial operations and the veterinary oncology and business operations. ImpriMed is also supported by strong advisors and key opinion leaders in the fields. Dr. Lim ended his presentation that ImpriMed has 30 full-time provisions in total to provide the best predictive information to doctors and with their goal to make a world without any more trial and error on beloved animals.

Image Sources: Zoom Presentation Screenshot by Dr. Sungwon Lim